Evidence map›Paper›PMID 14576328›Full record

ArticleNucleic acids research2003

Exploiting features of adenovirus replication to support mammalian kinase production.

Matt Cotten, Kerstin Stegmueller, Jan Eickhoff, Miriam Hanke, Katrin Herzberger, Thomas Herget, Axel Choidas, Henrik Daub, Klaus Godl

Open access · bronzeAbstract read
In one paragraph

Article in Nucleic acids research, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. An efficient proteomics method to identify the cellular targets of protein kinase inhibitors.Proceedings of the National Academy of Sciences of the United States of America · 2003
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 2 countries.

Matt CottenAxxima Pharmaceuticals AG, Max-Lebsche-Platz 32, 81377 München, Germany. matt.cotten@axxima.com
Kerstin Stegmueller
Jan Eickhoff
Miriam Hanke
Katrin Herzberger
Thomas Herget
Axel Choidas
Henrik Daub
Klaus Godl
Phenex Pharmaceuticals (Germany) · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Faced with the current wealth of genomic data, it is essential to have robust and reliable methods of converting DNA sequences into their functional gene products. We demonstrate here that when conditions are established that take advantage of the replication-associated virus amplification, the virus-induced shutdown of host protein synthesis as well as the activation of signalling pathways that normally occur during virus replication, adenovirus biology can be exploited to generate a potent kinase expression system. Residual virus in the protein production has always been a limitation for adenovirus systems and we describe a DNA intercalator/ultraviolet light treatment that eliminates residual adenovirus in protein preparations that has no deleterious effect on enzyme activity. The use of mammalian cells in combination with adenovirus generated a variety of active enzymes which could not be produced in Escherichia coli or baculovirus-infected insect cells. Thus, the utility of adenovirus-mediated enzyme expression as a versatile alternative to established protein production technologies is demonstrated.

Indexed as

MammalsVirus ReplicationAdenoviridaeAnimalsBaculoviridaeCell LineChromatography, AffinityDrug ContaminationEnzyme ActivationGenetic EngineeringHumansIntercalating AgentsMultienzyme ComplexesProtein KinasesRecombinant ProteinsTransfectionIntercalating AgentsMultienzyme ComplexesProtein KinasesRecombinant Proteins

Identifiers

PMID14576328
PMCPMC275485
OpenAlexW2090979423

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.